There were two positive results from the latest trials by Israel’s largest biotech. Patients who started Teva’s Laquinimod MS treatment early halted progression of the disease. Then Teva’s Azilect add-on treatment for Parkinson’s disease improved patients’ condition significantly.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000831784&fid=1725
http://www.globes.co.il/serveen/globes/docview.asp?did=1000831432&fid=1725